益气健脾口服液合并化疗治疗胃癌临床及实验研究

Clinical and Experimental Study in Treating Gastric Cancer with Replenishing Qi and Invigorating Spleen Oral Liquid Combined with Chemotherapy

益气健脾口服液合并化疗治疗胃癌６１例，与对照组４０例对比观察治疗。其结果显示因化疗引起的恶心呕吐发生率，治疗组比对照组明显减少（Ｐ＜０．０１）。治疗组的化疗完成率为９５％，对照组为７８％（Ｐ＜０．０１）；白细胞和血小板下降率，两组相比，Ｐ均＜０．０１。说明益气健脾口服液有较好的减轻甚则解除单纯化学药物治疗所引起的胃肠道及血像的毒、副反应。对治疗满１年以上的治疗组６０例患者进行了随访，其中１、３、５年生存率分别为９８．３６％、８２．６９％和６０．００％。治疗组中Ⅲ期患者５年生存率为５７．１４％。动物实验显示，益气健脾口服液对小鼠Ｂ１６肺转移抑制率为９２．２％和８３．７％，与对照组比较Ｐ＜０．０１。益气健脾口服液还可以提高动物对化疗药物的耐受量。

cases of the gastric cancers have been treated with Replenishing Qi and Invigorating Spleen(RQIS)combined with chemotherapy.The patients were divided into treated group and control group randomly,The results showed that:rate of the adverse effects,e.g.nausea,vomiting,anorexia,diarrhea etc.were higher in the chemotherapy used patients,combined treated groups were lower significantly(P<0.01～0.001).Rate of chemotherapy completion was 95% in the treated group,78% in control group,the difference was significant(P<0.01).WBC and blood platelet were reduced in the treatment group and chemotherapy group, they were 30% and 45% respectively(P<0.01).Superoxide dismutase was increased obviously(P<0.01).It revealed that RQIS could scavenge the free redical potently.60 cases of gastric cancers have been treated over 1 year, the survival rates of 1 year,3 years,5 years were 98.36%,82.69%,60.00% respectively after following up.Among them,survival rate of Ⅲ stage patients was 57. 14%. Animal experimental study showed that the inhibiton rates of lung metastasis were 92.2% and 83.7% in mice B16 of RQIS groups.The difference was significant than that of control group.They could elevate the tolerance to chemotherapy in mice.